The National Pharmaceutical Pricing Authority announced that, effective 9 November 2026, it will cap trade margins at 30 % for 137 identified non‑scheduled anti‑cancer drug formulations, potentially reducing maximum retail prices by up to 70 % depending on existing price structures. The move is aimed at curbing excessive margins in the distribution chain and making cancer treatment more affordable. The list includes immunotherapy agents such as pembrolizumab, durvalumab and osimertinib, as well as denosumab, pegfilgrastim and bevacizumab. Manufacturers must notify the regulator of revised prices within seven days of the Gazette notification, and all sellers will be required to charge the new prices from 9 November.

Shares of hospital chains and pharmaceutical companies with oncology exposure traded lower in noon deals on Monday, 19 October, after the NPPA announcement. Max Healthcare, Apollo Hospitals, Sun Pharmaceutical Industries and Dr Reddy’s Laboratories all saw declines, reflecting market concern that the new pricing norms could squeeze revenue from anti‑cancer medicine sales through hospital pharmacies and distribution channels. Analysts noted that the impact on these firms will depend on their exposure to the 137 formulations, procurement costs and the contribution of medicine sales to their oncology business. The net effect on revenue and margins remains uncertain at this stage.

The NPPA has invoked Paragraph 19 of the Drugs (Prices Control) Order, 2013, to implement trade margin rationalisation (TMR). Under this framework, manufacturers must submit revised prices within seven days of the Gazette notification, and hospitals, retailers and other sellers will be required to charge the revised prices from 9 November. The 137‑formulation list covers widely used anti‑cancer drugs such as pembrolizumab, durvalumab, osimertinib, denosumab, pegfilgrastim and bevacizumab, along with other immunotherapy agents. The 30 % trade‑margin cap does not automatically translate into an equivalent reduction in manufacturers’ realisations or profits, meaning the impact on earnings cannot be determined without assessing product‑level exposure.

Max Healthcare and Apollo Hospitals are expected to see a potential decline in revenue from anti‑cancer medicine sales through their hospital pharmacies, according to analysts and news reports. The overall impact will depend on each chain’s exposure to the 137 formulations, procurement costs and the share of medicine sales in their oncology business. Lower drug prices could improve affordability and access to treatment, potentially boosting patient volumes over time, but the net effect on revenue and margins remains uncertain. The companies have not yet disclosed detailed exposure data, leaving investors to monitor subsequent earnings releases for clarity.

Sun Pharmaceutical Industries and Dr Reddy’s Laboratories, both with oncology portfolios, will also be affected by the new pricing norms, but the extent depends on which of their medicines are covered and how the revised margins influence their sales and distribution arrangements. The 30 % cap applies to trade margins and does not automatically reduce manufacturers’ realisations or profits, so the impact on earnings cannot be determined without assessing product‑level exposure. While the announcement may trigger short‑term stock movements, the long‑term effect on earnings will hinge on the contribution of the notified products to each company’s overall business.